Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy

Simple Summary The abundance and the dynamic of the studies on NSCLC require frequent summaries of the current achievements in the field. In our review, we aimed to update the status of knowledge about NSCLC, combining its epidemiology, classification novelties, tumor molecular basis, and two of the most promising approaches in cancer treatment: targeted therapy and immunotherapy. Non-small cell lung cancer (NSCLC) is a subtype of the most frequently diagnosed cancer in the world. Its epidemiology depends not only on tobacco exposition but also air quality. While the global trends in NSCLC incidence have started to decline, we can observe region-dependent differences related to the education and the economic level of the patients. Due to an increasing understanding of NSCLC biology, new diagnostic and therapeutic strategies have been developed, such as the reorganization of histopathological classification or tumor genotyping. Precision medicine is focused on the recognition of a genetic mutation in lung cancer cells called driver mutation to provide a variety of specific inhibitors of improperly functioning proteins. A rapidly growing group of approved drugs for targeted therapy in NSCLC currently allows the following mutated proteins to be treated: EGFR family (ERBB-1, ERBB-2), ALK, ROS1, MET, RET, NTRK, and RAF. Nevertheless, one of the most frequent NSCLC molecular sub-types remains without successful treatment: the K-Ras protein. In this review, we discuss the current NSCLC landscape treatment focusing on targeted therapy and immunotherapy, including first- and second-line monotherapies, immune checkpoint inhibitors with chemotherapy treatment, and approved predictive biomarkers.

Automated summary

Non-small cell lung cancer (NSCLC) is a common type of cancer worldwide, with its incidence influenced by various factors. With an increasing understanding of NSCLC biology, new treatment strategies such as targeted therapy and immunotherapy continue to emerge. However, successful treatment for certain molecular sub-types remains a challenge.